These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6101957)

  • 1. Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.
    Day JM; Houston JB
    Br J Clin Pharmacol; 1980 Jan; 9(1):91-4. PubMed ID: 6101957
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis.
    Allgayer H; Kruis W; Eisenburg J; Paumgartner G
    Eur J Clin Pharmacol; 1984; 26(2):275-7. PubMed ID: 6144549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.
    Das KM; Eastwood MA
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):514-20. PubMed ID: 241531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.
    Bates TR; Blumenthal HP; Pieniaszek HJ
    Clin Pharmacol Ther; 1977 Dec; 22(6):917-27. PubMed ID: 21768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulphasalazine treatment during breast feeding.
    Järnerot G; Into-Malmberg MB
    Scand J Gastroenterol; 1979; 14(7):869-71. PubMed ID: 44005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of rifampicin on sulphapyridine plasma concentrations following sulphasalazine administration.
    Shaffer JL; Houston JB
    Br J Clin Pharmacol; 1985 Apr; 19(4):526-8. PubMed ID: 2859874
    [No Abstract]   [Full Text] [Related]  

  • 7. Azo reduction of sulphasalazine in healthy volunteers.
    Houston JB; Day J; Walker J
    Br J Clin Pharmacol; 1982 Sep; 14(3):395-8. PubMed ID: 6127096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites.
    Järnerot G; Into-Malmberg MB; Esbjörner E
    Scand J Gastroenterol; 1981; 16(5):693-7. PubMed ID: 6119765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the single dose pharmacokinetics of sulphasalazine in rheumatoid arthritis and inflammatory bowel disease.
    Astbury C; Taggart AJ; Juby L; Zebouni L; Bird HA
    Ann Rheum Dis; 1990 Aug; 49(8):587-90. PubMed ID: 1975737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets.
    Pieniaszek HJ; Resetarits DE; Wilferth WW; Blumenthal HP; Bates TR
    J Clin Pharmacol; 1979 Jan; 19(1):39-45. PubMed ID: 33201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time course of free and N4-acetylated sulfapyridine concentrations in the plasma and saliva of man after sulfasalazine (salicylazosulfapyridine) administration: preliminary findings.
    Bates TR; Blumenthal HP; Pieniaszek HJ
    Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):183-9. PubMed ID: 9675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
    Bondesen S; Nielsen OH; Schou JB; Jensen PH; Lassen LB; Binder V; Krasilnikoff PA; Danø P; Hansen SH; Rasmussen SN
    Scand J Gastroenterol; 1986 Aug; 21(6):693-700. PubMed ID: 2875518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation.
    Esbjörner E; Järnerot G; Wranne L
    Acta Paediatr Scand; 1987 Jan; 76(1):137-42. PubMed ID: 2882643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
    Klotz U
    Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.
    Sharp ME; Wallace SM; Hindmarsh KW; Brown MA
    Eur J Clin Pharmacol; 1981; 21(3):243-50. PubMed ID: 6119205
    [No Abstract]   [Full Text] [Related]  

  • 16. Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis.
    Cowan GO; Das KM; Eastwood MA
    Br Med J; 1977 Oct; 2(6094):1057-9. PubMed ID: 21720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orocecal transit time in humans assessed by sulfapyridine appearance in saliva after sulfasalazine intake.
    Dhôte R; Bergmann JF; Leglise P; Chassany O; Elkharrat D; Conort O; Caulin C
    Clin Pharmacol Ther; 1995 Apr; 57(4):461-70. PubMed ID: 7712676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease.
    Shaffer JL; Kershaw A; Houston JB
    Br J Clin Pharmacol; 1986 Apr; 21(4):431-5. PubMed ID: 2871853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Estimations of the serum levels of sulfapyridine on patients treated with sulfasalazin (author's transl)].
    Eitner K; Hippius M; Reinicke C
    Dtsch Z Verdau Stoffwechselkr; 1982; 42(1):14-9. PubMed ID: 6122556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter: Salicylazosulfapyridine in clinical practice.
    Daz KM
    Gastroenterology; 1974 Feb; 66(2):326. PubMed ID: 4149356
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.